Since then, a larger number of patients with non-Hodgkin's lymphoma have been treated at Stanford with idiotype-pulsed DCs and the efficacy confirmed. In addition, pilot clinical trials of antigen-pulsed DCs have been conducted at Stanford in various types of cancer, including prostate cancer, colorectal cancer, multiple myeloma, and non-small cell lung cancer. These studies, and other studies carried out elsewhere, show that antigen-loaded DC vaccinations represent a safe and promising form of immunotherapy for a wide range of malignancies.
No comments:
Post a Comment